Insider Transactions Reported by 31 Insiders of CRESCENT BIOPHARMA, INC.

Symbol: CBIO on Nasdaq
Location: Waltham, MA

Key facts

CBIO - CRESCENT BIOPHARMA, INC. has 31 insiders with reported activity on this page.
Net insider value flow over the last year: +$19,999,999.
Recent transaction rows are available for direct filing-level review.

Change

Buy value: $19,999,999; sell value: $0.
Net share flow: +1,491,434.

Research use

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$19,999,999.

Buys

$19,999,999

Shares: 1,491,434

Insiders: 1

Sells

Shares: 0

Insiders: 0

Net

+$19,999,999

Shares: +1,491,434

Insiders: 1

Window (months)	Buy shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	1,491,434	$19,999,999	$0	+$19,999,999
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

CRESCENT BIOPHARMA, INC. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Fairmount Funds Management LLC	Director, 10%+ Owner	$60,557,872	+$19,999,999	+49%	Filing P/S	04 Dec 2025
Scott D. Sandell	10%+ Owner	$5,279,783			Mixed	25 Jan 2023
Joshua T. Brumm	Chief Executive Officer, Director	$4,878,636			Mixed	15 Dec 2025
Jonathan McNeill	President and COO	$2,408,381			Mixed	15 Dec 2025
Siren, L.L.C.	10%+ Owner	$2,294,139			Mixed	25 Jul 2024
Rachel K. King	Director	$1,545,582			Mixed	01 May 2024
Invus Public Equities, L.P.	10%+ Owner	$1,211,077			Filing P/S	07 Aug 2024
Christopher Grant Doughty	Chief Business Officer	$937,885			Mixed	15 Dec 2025
John L. Magnani	SVP of Research, CSO	$875,378			Mixed	11 Nov 2022
Chinmaya Rath	SVP and Chief Business Officer	$380,380			Mixed	12 Jan 2024
Jan Pinkas	Chief Scientific Officer	$339,405			Mixed	15 Dec 2025
Bruce S. Johnson	SVP & Chief Commercial Officer	$327,993			Mixed	12 Jan 2024
Ellie Eunkyung Im	Chief Medical Officer	$321,173			Mixed	15 Dec 2025
Daniel M. Junius	Director	$295,377			Mixed	01 May 2024
Richard William Scalzo	Chief Financial Officer	$292,883			Mixed	15 Dec 2025
Barbara Harlin Bispham	General Counsel and Corporate Secretary.	$277,803			Mixed	15 Dec 2025
Ryan Lynch	Treasurer, Senior Vice President of Finance and Chief Accounting Officer.	$186,660			Mixed	15 Dec 2025
Edwin Rock	Chief Medical Officer	$181,736			Filing P/S	20 Jun 2024
Patricia S. Andrews	Director	$138,315			Mixed	01 May 2024
Mark Alan Goldberg	Director	$108,975			Mixed	01 May 2024
Scott Koenig	Director	$86,730			Mixed	01 May 2024
Armand Girard	SVP, Chief Business Officer	$68,820			Mixed	11 Nov 2022
Brian M. Hahn	SVP Finance, CFO	$17,498			Filing P/S	18 Jun 2024
Jonathan Violin	Director	$14,598			Mixed	23 Jun 2025
BVF PARTNERS L P/IL	10%+ Owner	$13,100			Mixed	13 Jun 2025
Susan Moran	Director				Mixed	23 Jun 2025
Timothy R. Pearson	Director				Mixed	01 May 2024
Harout Semerjian	Chief Executive Officer, Director				Mixed	12 Jan 2024
David Charles Lubner	Director				Mixed	23 Jun 2025
Scott Thomas Jackson	Director				Mixed	01 May 2024
Alexandra Balcom	Director				Mixed	23 Jun 2025

Top shareholders of CRESCENT BIOPHARMA, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Fairmount Funds Management LLC	13D/G 3/4/5 13F	Director, 10%+ Owner · Company	19%	5,643,482	$73,252,396	+$32,700,021	04 Dec 2025	13D/G 3/4/5 13F
FMR LLC	13F 13D/G	Company	15% from 13D/G	4,133,514	$75,932,653	—	31 Mar 2026	13F 13D/G
1Globe Capital LLC	13D/G	—	10%	1,425,432	$20,839,816	+$7,729,886	07 Oct 2025	13D/G
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	10%	1,387,863	$18,736,150	$0	30 Jun 2025	13D/G
Venrock Healthcare Capital Partners III, L.P.	13D/G	—	9.5%	2,666,064	$29,460,007	$0	31 Dec 2025	13D/G
ForGrowth III PA B.V.	13D/G	—	6.1%	1,677,852	$21,778,519	$0	08 Dec 2025	13D/G
BALYASNY ASSET MANAGEMENT L.P.	13D/G 13F	Company	5.5%	1,510,033	$29,294,640	$0	31 Mar 2026	13D/G 13F
Vestal Point Capital, LP	13F 13D/G	Company	5.4% from 13D/G	1,500,000	$27,555,000	—	31 Mar 2026	13F 13D/G
TANG CAPITAL MANAGEMENT LLC	13D/G 13F	Company	4.2%	1,160,000	$22,504,000	+$8,924,000	31 Mar 2026	13D/G 13F
Logos Global Management LP	13F 13D/G	Company	4.1% from 13D/G	482,500	$8,863,525	—	31 Mar 2026	13F 13D/G
Adage Capital Management, L.P.	13D/G	—	0.37%	50,912	—	$0	20 Jun 2025	13D/G
Weinstein Benjamin	13D/G	—	0.1%	50,000	$12,000	$0	30 Oct 2024	13D/G
BVF INC/IL	13F	Company	10%	2,748,763	$50,494,776	—	31 Mar 2026	13F
Venrock Adviser, LLC	13F	Company	7.7%	2,133,576	$39,193,791	—	31 Mar 2026	13F
FCPM III SERVICES B.V.	13F	Company	6.1%	1,677,852	$30,822,141	—	31 Mar 2026	13F
Opaleye Management Inc.	13F	Company	4.8%	1,312,615	$24,112,738	—	31 Mar 2026	13F
Boxer Capital Management, LLC	13F	Company	3.3%	453,686	$8,334,212	—	31 Mar 2026	13F
VANGUARD CAPITAL MANAGEMENT LLC	13F	Company	2.9%	801,395	$14,721,626	—	31 Mar 2026	13F
Remedium Capital Partners, LLC	13F	Company	2.6%	361,250	$6,636,163	—	31 Mar 2026	13F
Deep Track Capital, LP	13F	Company	1.6%	453,686	$8,334,212	—	31 Mar 2026	13F
NEXTBio Capital Management LP	13F	Company	1.4%	372,856	$6,849,365	—	31 Mar 2026	13F
RTW INVESTMENTS, LP	13F	Company	1.4%	372,856	$6,849,365	—	31 Mar 2026	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.2%	323,553	$5,943,669	—	31 Mar 2026	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	1.1%	303,551	$5,577,000	—	31 Mar 2026	13F
Point72 Asset Management, L.P.	13F	Company	1.1%	300,000	$5,511,000	—	31 Mar 2026	13F
Alyeska Investment Group, L.P.	13F	Company	0.96%	264,000	$4,849,680	—	31 Mar 2026	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.83%	228,475	$4,197,086	—	31 Mar 2026	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.78%	213,635	$3,924,475	—	31 Mar 2026	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.75%	206,942	$3,801,525	—	31 Mar 2026	13F
MARSHALL WACE, LLP	13F	Company	0.73%	200,780	$3,688,328	—	31 Mar 2026	13F
Exome Asset Management LLC	13F	Company	0.56%	153,191	$2,814,119	—	31 Mar 2026	13F
JENNISON ASSOCIATES LLC	13F	Company	0.56%	152,974	$2,810,132	—	31 Mar 2026	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.47%	130,500	$2,397,285	—	31 Mar 2026	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.42%	115,828	$2,127,760	—	31 Mar 2026	13F
BlackRock, Inc.	13F	Company	0.42%	115,725	$2,125,869	—	31 Mar 2026	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.38%	104,221	$1,915,947	—	31 Mar 2026	13F
Hudson Bay Capital Management LP	13F	Company	0.32%	88,867	$1,632,486	—	31 Mar 2026	13F
Stonepine Capital Management, LLC	13F	Company	0.31%	85,000	$1,561,450	—	31 Mar 2026	13F
UBS Group AG	13F	Company	0.3%	82,706	$1,519,309	—	31 Mar 2026	13F
Burkehill Global Management, LP	13F	Company	0.27%	74,000	$1,359,380	—	31 Mar 2026	13F
Woodline Partners LP	13F	Company	0.27%	74,000	$1,359,380	—	31 Mar 2026	13F
ADAR1 Capital Management, LLC	13F	Company	0.18%	50,273	$923,515	—	31 Mar 2026	13F
VANGUARD FIDUCIARY TRUST CO	13F	Company	0.18%	49,423	$907,901	—	31 Mar 2026	13F
Quadrature Capital Ltd	13F	Company	0.15%	20,917	$384,245	—	31 Mar 2026	13F
JPMORGAN CHASE & CO	13F	Company	0.15%	41,004	$681,486	—	31 Mar 2026	13F
STATE STREET CORP	13F	Company	0.14%	39,067	$717,661	—	31 Mar 2026	13F
BARCLAYS PLC	13F	Company	0.11%	30,189	$554,572	—	31 Mar 2026	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.11%	29,277	$537,818	—	31 Mar 2026	13F
Lighthouse Investment Partners, LLC	13F	Company	0.09%	25,000	$459,250	—	31 Mar 2026	13F
MOORE CAPITAL MANAGEMENT, LP	13F	Company	0.09%	25,000	$459,250	—	31 Mar 2026	13F

Recent Insider Transactions by Companies or Individuals for CRESCENT BIOPHARMA, INC.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Jan Pinkas	GLYC	Ordinary Shares	Award				22,507	22,507	15 Dec 2025	Direct
Jan Pinkas	GLYC	Stock Option (Right to Buy)	Award				70,025	70,025	15 Dec 2025	Direct
Christopher Grant Doughty	GLYC	Ordinary Shares	Award	57.5%			22,714	62,194	15 Dec 2025	Direct
Christopher Grant Doughty	GLYC	Stock Option (Right to Buy)	Award				58,855	58,855	15 Dec 2025	Direct
Joshua T. Brumm	GLYC	Ordinary Shares	Award	20.5%			55,117	323,517	15 Dec 2025	Direct
Joshua T. Brumm	GLYC	Stock Option (Right to Buy)	Award				180,467	180,467	15 Dec 2025	Direct
Richard William Scalzo	GLYC	Ordinary Shares	Award				19,422	19,422	15 Dec 2025	Direct
Richard William Scalzo	GLYC	Stock Option (Right to Buy)	Award				57,688	57,688	15 Dec 2025	Direct
Jonathan McNeill	GLYC	Ordinary Shares	Award	19%			25,507	159,707	15 Dec 2025	Direct
Jonathan McNeill	GLYC	Stock Option (Right to Buy)	Award				78,029	78,029	15 Dec 2025	Direct
Ellie Eunkyung Im	GLYC	Ordinary Shares	Award				21,298	21,298	15 Dec 2025	Direct
Ellie Eunkyung Im	GLYC	Stock Option (Right to Buy)	Award				65,190	65,190	15 Dec 2025	Direct
Ryan Lynch	GLYC	Ordinary Shares	Award				12,378	12,378	15 Dec 2025	Direct
Ryan Lynch	GLYC	Stock Option (Right to Buy)	Award				33,512	33,512	15 Dec 2025	Direct
Barbara Harlin Bispham	GLYC	Ordinary Shares	Award				18,422	18,422	15 Dec 2025	Direct
Barbara Harlin Bispham	GLYC	Stock Option (Right to Buy)	Award				72,185	72,185	15 Dec 2025	Direct
Jonathan McNeill	GLYC	Stock Option (Right to Buy)	Award				172,836	172,836	08 Dec 2025	Direct
Joshua T. Brumm	GLYC	Stock Option (Right to Buy)	Award				345,672	345,672	08 Dec 2025	Direct
Fairmount Funds Management LLC	GLYC	Ordinary Shares	Purchase	98%	$18,237,600	$13.41	1,360,000	2,747,866	04 Dec 2025	By Fairmount Healthcare Fund II L.P.
Fairmount Funds Management LLC	GLYC	Pre-Funded Warrant (Right to Buy)	Purchase	8.03%	$1,762,399	$13.41	131,434	1,768,140	04 Dec 2025	By Fairmount Healthcare Fund II L.P.
Jan Pinkas	GLYC	Stock Option (Right to Buy)	Award				142,474	142,474	16 Jul 2025	Direct
Susan Moran	GLYC	Stock Option (Right to Buy)	Award				9,023	9,023	23 Jun 2025	Direct
Fairmount Funds Management LLC	GLYC	Stock Option (Right to Buy)	Award				9,023	9,023	23 Jun 2025	By: Peter Harwin
Jonathan Violin	GLYC	Stock Option (Right to Buy)	Award				9,023	9,023	23 Jun 2025	Direct
Alexandra Balcom	GLYC	Stock Option (Right to Buy)	Award				9,023	9,023	23 Jun 2025	Direct
David Charles Lubner	GLYC	Stock Option (Right to Buy)	Award				9,023	9,023	23 Jun 2025	Direct
Bvf Partners L P/Il	GLYC	Common Stock	Other				1,270,004	707,116	13 Jun 2025	Direct
Bvf Partners L P/Il	GLYC	Pre-Funded Warrants to Purchase Common Stock	Other				587,557	304,098	13 Jun 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.